RalphVBocciaMD

Oncology • Bethesda, MD

Center for Cancer and Blood Disorders

Join to view full profile

Dr. Boccia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boccia's full profile

Already have an account?

Office
6410 Rockledge Dr
Suite 660
Bethesda, MD 20817
Phone+1 301-571-0019

Fax+1 301-571-0988

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1980 - 1981
University of Minnesota Medical School

Certifications & Licensure

CA State Medical License 1980 - Present
MD State Medical License 1983 - 2026
DC State Medical License 2002 - 2024
NJ State Medical License 2015 - 2019
MN State Medical License 1978 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
Unknown status
Phase 2
A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 2
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome Start of enrollment: 2004 Aug 01
Terminated
Phase 2
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting Start of enrollment: 2006 Aug 01
Terminated
Phase 4
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
Completed
Phase 2
Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Start of enrollment: 2009 Apr 01
Terminated
Phase 2
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment Start of enrollment: 2012 Jul 01
Terminated
Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Start of enrollment: 2014 Apr 01
Recruiting
Phase 3
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Feb 05
Terminated
Phase 3
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Start of enrollment: 2014 Jul 14
Completed
Phase 3
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26
Completed
Phase 1, Phase 2
Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Start of enrollment: 2015 Dec 01
Completed
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) Start of enrollment: 2017 Feb 15
Completed
Phase 1
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Start of enrollment: 2020 Jun 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

77 citations
Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G. Berdeja, Yasmin Abaza, Elias J. Jabbour
Cancer. 2017-03-15
512 citations
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Dirix, István Takács, Guy Jerusalem, Petros Nikolinakos, Hendrik Tobias Arkenau
Breast Cancer Research and Treatment. 2018-10-23
85 citations
CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael A. Harb
Blood. 2016-06-30

Journal Articles

Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR
Ruben Niesvizky, David Siegel, Ralph Boccia, Blood

Abstracts/Posters

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis
Ralph Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy and Safety of Ferric Carboxymaltose Injection in Reducing Anemia in Patients Receiving Chemotherapy for Non-Myeloid Malignancies: A Phase 3, Placebo-Controlle...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
Ralph V. Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients
Ralph Boccia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Severe Hypophosphatemia in Patients with Cancer Following IV Iron Treatment: Results from a Large Comparative Trial
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

MediMergent Leverages Patient-Centric Real-World Data and Evidence Platform to Capture the Voice of the Patient in National Cancer TrialMarch 29th, 2023
Fostamatinib More Effective Earlier in Treatment for Immune ThrombocytopeniaDecember 1st, 2020
VerdePharmHealth and Altopa Enter into Exclusive Partnership Agreement for Patient-Centric CBD FormulationsSeptember 15th, 2020
Join now to see all